



Veterinary Vaccine: Early-phase Development
Bottlenecks in the process are marked with a B.
All are standard proces unless stated otherwise.
Vaccine candidate – laboratory testing
- Lead(s) identification
- Pre-GMP Masterseed bank (essential go/no go step) B
- Lead(s) Development
- Re-cloning, strain development and antigen presentation B
- Vaccine characterisation, formulation and adjuvantisation B
- Quality Control, Stability testing (essential go/no go step)
- GMP master seed banks B
- Process development B
- Process Design
- Process Analytics (1. In process controls, 2. Product/Impurities Characterisation, 3. Release Assays (QA/QC) )
- Process Flowsheet and optimisation (1. Process Flow sheet, 2. Critical Process Parameters (CPP)/Critical Quality Attributes (CQA)s, 3. SOPs and sample data, 4. Master Seed Bank transfer and testing)
- Pilot scale-up studies
- Use of pilot lots in developmental studies
- Produce minimum and maximum potency batches B
- Potency assay (essential go/no go step)
- Quality, purity and consistency: Starting materials, Manufacturing process, Process quality control, Product quality control (essential go/no go step) B
- Checklist: Efficacious, Prelliminary correlates of protection, Quality of product, Acceptable titres, Stable formulation (essential go/no go step)
- In vivo safety: Maximum titre/potency, Single, repeat (overdose), Minimal age, Pregnant animals, Live vaccine studies B
- In vivo efficacy: Minimum titre/potency, Onset of immunity, Duration of immunity, Minimal age, Requirement for boosters, Impact of maternally derived antibodies, Immune mechanism B
- Analysis of immune response: efficacy and safety of formulation, correlates of protection. (If favourable continue to Step 12, if unfavourable go back to Step 3)
- Lead product(s) identified (essential go/no go step)
- Reassess TPP
- QC and stability testing
- Fill/finish
- Engineering batches to finalise process
- Environmental safety, Consumer safety, User safety (essential go/no go step) (If unfavourable go back to Step 3)
- GMP manufacture (BULK) B
- QC and stability testing
- GMP manufacture (fill/finish) B
- Field trial Application (ATC) (essential go/no go step)
- Late-phase Development and registration
- Tech transfer documents if manufacturing at scale (SOPs, TPP) (optional)
The following steps 8 to 11 are in parallel.
Process Validation and Manufacturing scale-up
The following steps 14 to 17 are in parallel.
Ongoing throughout process:
- Regulatory Affairs and ethical considerations - UK and 'in country' where vaccine may be tested
- Target product profile
Next list view of map – Late-phase Development and Registration Map